Description du projet
Un nouveau médicament biologique contre les maladies auto-immunes
La polyarthrite rhumatoïde (PR) et la polyarthrite juvénile idiopathique (PJI) sont des affections chroniques et débilitantes qui affectent respectivement environ 1 % de la population adulte et des milliers d’enfants dans le monde. Les thérapies actuelles, qui agissent en supprimant le système immunitaire du patient, échouent chez près de 30 % des personnes traitées. Le projet Notid financé par l’UE a pour objectif de proposer un nouveau médicament ciblant les protéines dans le traitement des maladies inflammatoires chroniques. Les résultats préliminaires sont prometteurs et indiquent que le médicament peut être utilisé pour traiter un éventail de maladies auto-immunes et auto-inflammatoires, améliorant ainsi la qualité de vie des patients.
Objectif
Lipum AB has discovered a novel target protein for treatment of chronic inflammatory diseases. We are now developing a biological drug that will inhibit the target molecule. We propose an entirely new therapeutic mode of action as an alternative to current therapeutics that do not provide adequate response in as much as 1/3 of patients. Our research and preclinical results indicate that our approach can be applied for treatment of an array of autoimmune and autoinflammatory conditions, and that the suppression of the patient immune system can be avoided, which otherwise is a common negative side effect limiting treatment options. Currently, Lipum is focused on delivering a humanised candidate drug. Our aim is to to reach a drug development phase where toxicology and safety tests can be started and establish collaborations needed to proceed with the clinical studies. Within the lifecycle of this project, Lipum will focus on providing preclinical evidence, securing IP and reaching out to partners interested in exploitation of our approach for the treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis. These are chronic and debilitating conditions that affect around 1% of adult population (RA) or thousands of children (JIA) worldwide. Both RA and JIA are important cause of disability and generate high costs of healthcare and lost productivityLipum AB is a Swedish SME founded in 2010 with the aim to bring to the market a new biological drug for chronic inflammatory diseases. An effective and safe alternative has been long expected by the millions of patients that struggle with chronic and debilitating conditions like Rheumatoid arthritis (RA), Psoriatic Arthritis (PsA), or Inflammatory Bowel Disease (IBD), and by the rheumatology opinion leaders that have been highlighting the unmet clinical need in this domain. Apart from the patients’ well-being and quality of life, chronic inflammatory diseases incur high social costs of healthcare and lost productivity.
Champ scientifique
- medical and health sciencesclinical medicinerheumatology
- medical and health scienceshealth sciencesinflammatory diseases
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesclinical medicinegastroenterologyinflammatory bowel disease
- medical and health sciencesbasic medicineimmunologyautoimmune diseases
Programme(s)
Régime de financement
SME-2 - SME instrument phase 2Coordinateur
907 36 UMEA
Suède
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.